BLOC-1 related complex subunit 6Genealiases: C17orf59 · PRO2472
Q-omics provides the consensus-scored BORCS6 profile across patient tissues and cancer cell-line models. BORCS6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BORCS6 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, BORCS6 RNA expression shows 18,656 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LIHC, and ACC as cancer lineages where BORCS6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BORCS6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BORCS6 survival associations across molecular data types. BORCS6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BORCS6 RNA expression–survival associations across cancer types. High BORCS6 expression shows unfavorable associations in COAD and UCS, but favorable associations in UVM, KIRC, UCEC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for BORCS6 RNA expression.
This table summarizes BORCS6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BORCS6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BORCS6 shows lower tumor expression in COAD, UCEC, KICH and THCA and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher BORCS6 RNA expression in tumor versus normal tissue (log2 FC = +1.198, t-test p < 0.001).
This table shows molecular features associated with BORCS6 in patient tissues and cancer cell lines. In patient samples, BORCS6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BORCS6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
